PDF Cover

Margetuximab Market

The market for Margetuximab was estimated at $240 million in 2024; it is anticipated to increase to $341 million by 2030, with projections indicating growth to around $456 million by 2035.

Report ID:DS1802325
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Margetuximab
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Margetuximab Market Outlook

Revenue, 2024

$240M

Forecast, 2034

$430M

CAGR, 2025 - 2034

6.0%

The Margetuximab industry revenue is expected to be around $254.7 million in 2025 and expected to showcase growth with 6.0% CAGR between 2025 and 2034. The significant growth observed in the Margetuximab market reflects its increasing importance in theindustry'slandscape today. This progress is largely fueled by factors such as the rising global incidence of HER2 positive cancers increased awareness about personalized treatments and advancements in monoclonal antibody therapies. With its therapeutic properties Margetuximab remains a valuable contender in the global market playing a vital role, in the constantly evolving realm of medical treatments.

Margetuximab, also known as Margenza, is a groundbreaking monoclonal antibody created to target HER2 cancer specifically for treatment purposes. It has received interest due to its distinctive approach and the possibility of enhancing treatment effectiveness beyond current options. Its use in addressing breast and gastric cancers stands out as notable applications. The increasing clinical evidence showcasing patient results has reinforced healthcare providers confidence, in adopting Margetuximab for treatment.

Margetuximab market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Margetuximab Market Outlook

Market Key Insights

  • The Margetuximab market is projected to grow from $240.3 million in 2024 to $430 million in 2034. This represents a CAGR of 6%, reflecting rising demand across Breast Cancer, Gastric Cancer, and Metastatic cancers.

  • MacroGenics Inc., Eli Lilly and Company, Amgen Inc. are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Margetuximab market and are expected to observe the growth CAGR of 3.9% to 5.8% between 2024 and 2030.

  • Emerging markets including Brazil, India and UAE are expected to observe highest growth with CAGR ranging between 6.9% to 8.3%.

  • Innovation in Therapeutic Approaches transition is widening cross-selling opportunities across the Margetuximab industry ecosystem, helping companies drive stronger adoption of their full product portfolio. This ecosystem pull-through is projected to add $4 million to Margetuximab industry product sales in 2025.

  • The Margetuximab market is set to add $190 million between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    growing prevalence of her2 positive cancers, and

    Advancements in Biotechnology and Drug Development, Margetuximab market to expand 79% between 2024 and 2034.

margetuximab market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Margetuximab - Country Share Analysis

Opportunities in the Margetuximab

One key growth plan for the medication Margetuximab involves forming partnerships, with pharmaceutical companies worldwide.

Growth Opportunities in North America and Europe

North America is expecting growth in the Margetuxiamb market due to its strong healthcare system and a good understanding of new cancer treatments along with substantial investments in research and development efforts driving the market forward in this region is the high prevalence of metastatic breast cancer and a supportive environment, for clinical trials The competition comes from well known biopharmaceutical companies offering various therapies which adds pressure for Margetuxiamb to stand out based on its clinical effectiveness and safety records The key prospects in this region involve forming partnerships with other entities and engaging with patients through outreach initiatives. Additionally utilizing precision medicine presents an opportunity, for growth and innovation.
Europe also plays a role in the global Margetuximb market with strong backing from the government for new medications and a growing elderly population contributing to its growth in the region along with an increase in HER2 positive cancers prevalence. Factors driving Margetuximbs growth in Europe include a number of patients seeking targeted treatments and advancements in genetic sequencing methods due, to supportive regulations. The competitive landscape is characterized by pharmaceutical companies possessing monoclonal antibody technologies internally and underlining the importance of effective market penetration strategies. Exciting possibilities are emerging in the realms of collaborations between private sectors, fresh deals with distributors and leveraging the personalized medicine efforts, in the region.

Market Dynamics and Supply Chain

01

Driver: Expansion of HER2-Positive Cancer Diagnoses and Demand for Enhanced Immunotherapy Agents

The increasing diagnosis rate of HER2-positive cancers, particularly breast and gastric cancers, is also a significant driver for margetuximab market growth. Improved screening protocols and widespread adoption of HER2 testing have also raised the number of identified patients eligible for HER2-targeted therapies. Earlier detection allows oncologists to integrate margetuximab into treatment sequences where traditional agents may also be less effective. Concurrently, advancements in immunotherapy and antibody engineering are also shaping oncology treatment paradigms. Margetuximab’s Fc-optimized design enhances immune cell engagement compared to earlier HER2 antibodies, generating stronger antibody-dependent cellular cytotoxicity. This technological innovation addresses unmet needs in patients with low immune response to conventional therapies. The convergence of better diagnostic capabilities and the evolution of engineered monoclonal antibodies increasingly positions margetuximab as a preferred option in precision oncology. Together, these trends enhance market adoption and long-term revenue prospects.
A key driver for margetuximab is also the rising demand for Fc-engineered monoclonal antibodies tailored to patient immune profiles. Clinicians are also increasingly aware that traditional monoclonal antibodies may also elicit variable immune responses based on patient genetics and tumor microenvironment. Margetuximab’s engineered Fc region increases affinity for activating Fc gamma receptors, improving immune-mediated tumor cell killing in select HER2-positive patients. This niche trend in personalized oncology reflects broader industry momentum toward customizing biologic therapies. As precision medicine adoption grows, therapies like margetuximab that offer superior immune engagement are also gaining preference over standard agents, accelerating uptake in competitive oncology portfolios.
02

Restraint: High Treatment Costs and Reimbursement Challenges Limit Margetuximab Adoption in Oncology Care

One of the leading restraints on margetuximab’s market expansion is its high treatment cost, which has led to reimbursement hurdles in many healthcare systems. Oncology drugs with substantial price tags often face strict payer evaluation processes, delaying formulary inclusion and restricting patient access. For example, in price-sensitive regions, clinicians may prescribe lower-cost HER2-targeted therapies like trastuzumab or biosimilars over margetuximab, even when incremental benefits are present. These financial barriers reduce demand and slow revenue growth, particularly in public healthcare markets where budget constraints drive preference for established, less expensive alternatives.
03

Opportunity: Targeting the Untapped Segment and Technological Innovations, Advancing Margetuximab

There is an opportunity for Margetuximab to expand its market presence by focusing on the overlooked group of individuals with HER2 positive cancers who currently lack effective treatment options available to them. This medication represents an approach in addressing the medical needs of these patients and provides a glimmer of hope for them. Additionally it holds promise for enhancing survival rates, which could potentially drive up its demand, in the market.
Future opportunities for growth may stem from technological progressions which involve enhancements in diagnostic instruments that can pinpoint individuals who would derive the greatest advantage, from Margetuximab therapy. If combined with its method of operation and the possibility of combined treatments it is possible that such advancements could result in a higher acceptance rate of Margetuximab.
04

Challenge: Competition from Established HER2 Therapies and Biosimilars Reduces Market Share Growth

Intense competition from well-established HER2-targeted therapies and emerging biosimilars is another critical restraint for margetuximab. Drugs such as trastuzumab, pertuzumab, and newer antibody-drug conjugates maintain strong clinical adoption due to extensive efficacy data and entrenched guidelines. Additionally, the rapid uptake of trastuzumab biosimilars has driven down category pricing, making alternatives more cost-attractive. For instance, in metastatic breast cancer treatment protocols, clinicians often favour combination regimens with proven agents, limiting margetuximab’s use to specific patient subsets. This competitive pressure dampens overall demand and constrains market penetration.

Supply Chain Landscape

1

Raw Material Acquisition

Bristol-Myers SquibbGilead Sciences
2

Research & Development

MacrogenicsRoche
3

Drug Manufacturing

AmgenEli Lilly
4

Marketing & Distribution

PfizerNovartis
Margetuximab - Supply Chain

Use Cases of Margetuximab in Breast Cancer & Metastatic cancers

Breast Cancer : Margetuximab is predominantly used in HER2-positive breast cancer, particularly in patients with advanced or metastatic disease who have received prior anti-HER2 therapies. It is an Fc-engineered monoclonal antibody designed to enhance immune activation by increasing affinity for activating Fc gamma receptors while reducing binding to inhibitory receptors. In clinical practice, it is mainly used by oncology specialists in combination with chemotherapy to improve antibody-dependent cellular cytotoxicity. Its unique advantage lies in offering clinical benefit to patients who show suboptimal response to trastuzumab, especially those with specific Fc receptor genotypes, supporting more personalized breast cancer treatment strategies.
Gastric Cancer : In gastric and gastroesophageal junction cancers, margetuximab is being explored for HER2-positive tumors where treatment options remain limited. It is typically evaluated in combination regimens under oncologist supervision, targeting patients who progress on standard HER2-directed therapies. The Fc-engineering of margetuximab provides enhanced immune engagement, which is particularly valuable in gastric cancer, where immune responsiveness is variable. This approach aligns with the growing trend toward immuno-oncology integration in gastrointestinal malignancies. Its potential to improve immune-mediated tumor killing positions margetuximab as a differentiated biologic therapy in a cancer segment with high unmet clinical need.
Metastatic cancers : For metastatic cancers, margetuximab is mainly applied in HER2-expressing tumors that have spread beyond the primary site, including heavily pretreated patient populations. It is used by medical oncologists as part of combination therapy strategies aimed at prolonging disease control rather than cure. The drug’s optimized Fc domain enhances natural killer cell activity, which is critical in metastatic settings where tumor immune evasion is common. This immune-focused mechanism offers an advantage over conventional monoclonal antibodies and supports its evaluation across multiple metastatic indications, reflecting broader industry interest in extending targeted biologics into advanced cancer management.

Recent Developments

Recent strategic developments for Margenza focus on expanding its role in HER2-positive oncology and reinforcing its position within targeted cancer therapy portfolios. Enhanced clinical data supporting improved antibody-dependent cellular cytotoxicity and real-world outcomes are encouraging uptake among oncologists. A key market trend is the integration of precision medicine and biomarker testing in treatment selection, which elevates demand for engineered monoclonal antibodies tailored to patient immune profiles. This trend aligns with broader shifts toward personalized oncology and optimized biologic drug utilization.

December 2024 : Macrogenics shared findings from a Phase III clinical study of Margetuximab as an initial therapy, for advanced breast cancer patients.
October 2024 : Germany has given the light to the utilization of Margetuximab alongside chemotherapy, for individuals dealing with advanced or metastatic HER positive breast cancer. This move is expected to expand the drugs presence in the market significantly.
August 2024 : Macrogenics acquired a manufacturing technique from BioProcess Solutions to expand the production of Margetuximab in response, to the growing worldwide need and to improve its distribution system.

Impact of Industry Transitions on the Margetuximab Market

As a core segment of the Pharmaceutical industry, the Margetuximab market develops in line with broader industry shifts. Over recent years, transitions such as Innovation in Therapeutic Approaches and Regulatory Advancements have redefined priorities across the Pharmaceutical sector, influencing how the Margetuximab market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Innovation in Therapeutic Approaches

A monoclonal antibody known as Margetuximab has emerged as an advancement in the field of oncology treatment for specific cancers. The introduction of Margetuximab has brought about changes in medical treatment practices and the pharmaceutical industry. In advanced HER2 positive breast cancer cases the utilization of Margetuximab has proven to be highly effective, resultng in better patient outcomes. This shift towards precision medicine and targeted therapies has sparked increased attention and interest, within these sectors.
02

Regulatory Advancements

Regulatory advancements surrounding margetuximab highlight a broader industry transition toward faster, evidence-driven approvals for innovative biologics. Authorization by regulators such as the FDA has validated Fc-engineered monoclonal antibodies, encouraging developers to pursue differentiated antibody designs rather than incremental biologic modifications. This shift accelerates time-to-market for targeted oncology therapies and influences clinical trial strategies, with greater emphasis on biomarker-defined patient populations. For example, contract research organizations and diagnostic companies benefit from increased demand for companion testing to support regulatory submissions. Manufacturing partners are also adapting to higher volumes of complex biologics. Overall, these regulatory shifts are reshaping biopharmaceutical development models, strengthening innovation pipelines, and reinforcing the role of monoclonal antibodies in precision cancer treatment.